China BioPharma Corp (fka CHBO)

[sweet crude]

Key points on CBPC - big!!!

INVESTMENT HIGHLIGHTS

- Market Growth – the market in China for flu vaccinations has grown from 3.9 million doses in 2000 to 22.3 million doses in 2005, or 30% year over year.
- Distribution Network – the company has the largest independent vaccine distribution network covering 268 cities in China.
- Strategic Alliances – the company retains a close relationship with the Chinese Center of Disease Control (CDC), providing local CDC vaccinations, and providing their high-capacity production facility for any potential epidemics within China.
- Product Pipeline – in addition to marketing vaccines for Influenza, Epidemic Hemorrhagic Fever, and Epidemic Japanese Encephalitis, the company is also conducting research such new products to cover allergies and avian bird flu.
- Revenue Projection – management anticipates generating $10 million in annual revenues and positive net income for fiscal year 2006.
- Management Experience – the company retains some of the top scientists within the human vaccine fields in China, and has had a number of years experience running a public company


got this from their fact sheet.....this is big!

link - http://www.theasianinvestor.com/reports/cbpc.htm